Skip to content
Screener

Biogen BIIB Q3 2025 earnings

Reported October 30, 2025 · Before market open

Revenue$2.5BBeat by $114.8M
EPS$4.81Beat by $0.93
Revenue estimate$2.3B
EPS estimate$3.88

Next report

Oct 29, 2026 (in 2 months)
Revenue estimate$2.6B
EPS estimate$2.04

Financials

Q3 2025

Income statement

See full
Revenue$2.5B+2.8%
Gross profit$1.9B+1.8%
Net income$466.5M+20.1%
EPS (diluted)$3.17+19.2%

Balance sheet

See full
Cash & equivalents$3.9B+127%
Total debt$6.6B+34.4%
Total equity$18.2B+11.3%
Total assets$29.2B+3.2%

Cash flow

See full
Operating cash flow$1.3B+36.0%
CapEx$46.2M+32.0%
Free cash flow$1.2B+36.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$20.54B-27.3%
Enterprise value$23.27B-26.0%
P/E12.8×-4.7×
P/S2×-0.9×

Profitability

See full
Gross margin75.2%-0.3pp
Net margin16%-0.8pp
FCF margin22.9%+2.1pp

Returns & leverage

See full
Return on equity9.3%-1.2pp
Debt / equity0.4×+0.1×
Current ratio2.7×+1.5×

Segments

By product

See full
TYSABRI$431.8M+6.3%
SPINRAZA$374.0M-1.9%
VUMERITY$214.6M+35.7%
AVONEX$188.5M+7.0%
TECFIDERA$168.2M-27.7%

By segment

See full
Reportable Segment$2.5B+2.8%

FAQ

When did Biogen report Q3 2025 earnings?
Biogen (BIIB) reported Q3 2025 earnings on October 30, 2025 before market open.
What were Biogen's Q3 2025 revenue and EPS?
Biogen reported revenue of $2.5B and eps of $4.81 for Q3 2025.
Did Biogen beat estimates in Q3 2025?
Revenue beat the consensus estimate of $2.3B by $114.8M. EPS beat the consensus estimate of $3.88 by $0.93.
How did Biogen's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 0.4% from $2.5B a year earlier and eps grew 17.9% from $4.08.
Where can I find Biogen's Q3 2025 SEC filings?
You can read the 8-K earnings release (0000875045-25-000047) and the 10-Q periodic report (0000875045-25-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.